{In Vivo} summarizes the technologies of several recently founded companies: Netherlands start-up [BioMaDe BV] will use nanotechnology to design and construct molecular devices for use in a variety of commercial applications. [DirectGene Inc.] is developing a tissue specific gene promoter technology for cancer gene therapy, based on the role of tumor-stromal interactions. [Esurg.com] will sell medical, surgical and pharmaceutical supplies and information to out-of-hospital healthcare providers. Founded in June 1999, [ImmunoGenec Biotechnologie GmbH] aims to develop, produce and market protein-based therapies for the immunotherapeutic treatment of certain cancers. [Quorex Pharmaceuticals Inc.] will discover anti-infectives using its discovery of a novel signaling pathway that occurs in wide variety of pathogenic bacteria. A joint venture of Rohm & Haas Co. and Argonex Inc, [RHeoGene LLC.] is developing enabling gene tools based on its proprietary Ecdyosyne Recepter-based gene switch system.
Summarizing the technologies of companies founded within the last year.
Nijenborgh 4
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
